CDC Guidelines for Management of Uncomplicated Chlamydia Infection

First‑Line Treatment

• Doxycycline 100 mg orally twice daily for 7 days is the preferred regimen for uncomplicated genital chlamydial infection in both men and women, achieving a ≈ 98 % microbiologic cure rate, costing less than azithromycin, and not associated with a higher risk of adverse events. 1

Alternative First‑Line Option

• Azithromycin 1 g orally as a single dose is an acceptable alternative, providing a ≈ 97 % cure rate that is essentially equivalent to doxycycline. It should be selected when patient adherence to a 7‑day course is doubtful, when follow‑up is unpredictable, or when directly observed therapy (DOT) is required. 2

Second‑Line Alternatives (when first‑line agents unavailable)

• Erythromycin base 500 mg orally four times daily for 7 days or erythromycin ethylsuccinate 800 mg orally four times daily for 7 days – less efficacious than doxycycline/azithromycin because gastrointestinal side effects often reduce compliance. 1
• Ofloxacin 300 mg orally twice daily for 7 days or levofloxacin 500 mg orally once daily for 7 days – more expensive and offer no dosing advantage over the preferred agents. 2

Special Population: Pregnancy

• Prenatal screening and treatment of chlamydia prevents neonatal infection (conjunctivitis and pneumonia). 3

Medication Dispensing & Directly Observed Therapy

• Medications should be dispensed on‑site with the first dose taken under direct observation to maximize adherence. 1

Patient Counseling

Sexual Abstinence

• Patients must abstain from sexual intercourse for 7 days after a single‑dose regimen or until the full 7‑day doxycycline course is completed, and continue abstinence until all sexual partners have been treated to avoid reinfection. 2

Partner Management

• All sexual partners must receive treatment to prevent reinfection of the index case and further transmission.
• When gonorrhea is diagnosed, presumptive concurrent treatment for both infections is appropriate. 2

Follow‑Up Testing

Test‑of‑Cure (Not Routinely Recommended)

• Routine test‑of‑cure at 3–4 weeks is not recommended for non‑pregnant patients treated with the recommended regimens. 1
• Test‑of‑cure is indicated only when:
• Testing before 3 weeks may yield false‑positive results from non‑viable organisms or false‑negative results from low‑level persistent infection. 2

Reinfection Screening (Strongly Recommended)

• All women with chlamydial infection should be retested approximately 3 months after treatment and again at their next medical visit within 3–12 months, regardless of partner treatment status, to detect the high rate of reinfection that raises the risk of pelvic inflammatory disease and other complications. 1
• Evidence for routine retesting of men is limited, though some clinicians recommend it. 1